[
  {
    "ts": null,
    "headline": "Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes",
    "summary": "Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs). Nik",
    "url": "https://finnhub.io/api/news?id=eaa52e97d7e7120857087208c94b69b10f9f6d48ce5651deeba46eca365e9644",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736980440,
      "headline": "Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes",
      "id": 132416870,
      "image": "https://media.zenfs.com/en/prnewswire.com/edd1b7e9f67c769d7894c96a98021730",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs). Nik",
      "url": "https://finnhub.io/api/news?id=eaa52e97d7e7120857087208c94b69b10f9f6d48ce5651deeba46eca365e9644"
    }
  },
  {
    "ts": null,
    "headline": "Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes",
    "summary": "By Sabela Ojea Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes. ...",
    "url": "https://finnhub.io/api/news?id=4ccf3846ddeef32053c990f47db795e3a5510b6c571ceffd3e9d6b1b48d3faa1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736965691,
      "headline": "Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes",
      "id": 132402140,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "By Sabela Ojea Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes. ...",
      "url": "https://finnhub.io/api/news?id=4ccf3846ddeef32053c990f47db795e3a5510b6c571ceffd3e9d6b1b48d3faa1"
    }
  },
  {
    "ts": null,
    "headline": "JP Morgan 2025: Incyte expects period of ‘defining catalysts’",
    "summary": "Incyte announced plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GvHD.",
    "url": "https://finnhub.io/api/news?id=49cefb58640941ca8c16eb218a5a29d105e047a7dbda5142a4aef7b837c11689",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736949268,
      "headline": "JP Morgan 2025: Incyte expects period of ‘defining catalysts’",
      "id": 132416871,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/01/GettyImages-2192875096.jpg",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte announced plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GvHD.",
      "url": "https://finnhub.io/api/news?id=49cefb58640941ca8c16eb218a5a29d105e047a7dbda5142a4aef7b837c11689"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines",
    "summary": "Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.",
    "url": "https://finnhub.io/api/news?id=d18cb1bff8c5c6751b15a08492198875b58ae3a911bb0ead698673c87e410e8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736930880,
      "headline": "Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines",
      "id": 132416872,
      "image": "https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines have been highlighted in this Industry Outlook article.",
      "url": "https://finnhub.io/api/news?id=d18cb1bff8c5c6751b15a08492198875b58ae3a911bb0ead698673c87e410e8d"
    }
  }
]